Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications

Author(s):  Zur Eyal

Issue:  Nov/Dec 2018 - Volume 22, Number 6
View All Articles in Issue

Page(s):  446-454

Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications Page 1
Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications Page 2
Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications Page 3
Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications Page 4
Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications Page 5
Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications Page 6
Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications Page 7
Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications Page 8
Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications Page 9

Download in electronic PDF format for $75

Abstract:  Radiotherapy and epidermal growth factor receptor inhibitors, as important representatives of current chemotherapy, are crucial and irreplaceable treatments of modern oncology. These two types of treatments frequently cause severe dose-dependent dermatologic adverse events that can negatively affect a patient’s quality of life and compliance and cause inappropriate dose reductions and even treatment brakes. This article aims to emphasize new scientific data, published in peer reviews, regarding new possibilities to manage these debilitating dermatological adverse events. Since part of the scientific findings is new, the responsibility to enable pharmacologic treatment is in the compounding pharmacist domain. The article also suggests new formulations to the new pharmacologic treatment.

Related Keywords: Eyal Zur, BSc Pharm, RPh, MBA, cancer medicine, medical oncology, radiotherapy, epidermal growth factor receptor inhibitors, EGFR, dermatologic adverse events, acneiform rash, paronychia, inflammation, mucositis, xerosis, pruritus, hair changes, inflammatory changes, fingernails, keratinocytes, formulation, heparinoid cream, heparinoid lotion, topical preparations, ivermectin cream, ivermectin lotion, 5-aminolevulinic acid hydrochloride cream, case reports, radiation dermatitis, propranolol hydrochloride, topical corticosteroids

Related Categories: CANCER AND AIDS, DERMATOLOGY, FORMULATIONS, CASE REPORTS, ADVERSE DRUG EVENTS, PREVENTIVE MEDICINE/WELLNESS

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications
Zur Eyal
Nov/Dec 2018
Pg. 446-454

Veterinary Transdermal Medications: A to Z
Davidson Gigi S
Mar/Apr 2003
Pg. 106-113

Sensitization Therapy for Warts
Kuntz Rachael
Jul/Aug 2003
Pg. 266-270

Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
Jul/Aug 2003
Pg. 288-291

Reversing Erectile Dysfunction and Urinary Incontinence After Prostatectomy or Radiotherapy: The Stanley Prostate-Cancer Treatment Protocol
McKettrick Greg
, Yoch Doug
Jan/Feb 2021
Pg. 18-23

Compounding with Biotechnology Products, Part 2: Product-specific Considerations
Allen Loyd V Jr
Nov/Dec 2022
Pg. 446-466

Gastrointestinal Mucositis: Focus on the Treatment of the Effects of Chemotherapy and Radiotherapy on the Rectum
Zur Eyal
Mar/Apr 2012
Pg. 117-124

The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women
Stephenson Kenna
, Neuenschwander Pierre F, Kurdowska Anna K
Jan/Feb 2013
Pg. 74-85

View Sample
Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia
Zur Eyal
Mar/Apr 2019
Pg. 113-119

Five Compounds for Treating Diabetes-Related Conditions
Meece Jerry
May/Jun 2003
Pg. 170-174

Excipients and Adverse Events
Allen Loyd V Jr
Sep/Oct 2023
Pg. 382-385

Sore Nipples in Breastfeeding Mothers: Causes and Treatments
Albright Lisa M
Nov/Dec 2003
Pg. 426-435

View Sample
Basics of Compounding for Dry-Skin Conditions
Allen Loyd V Jr
Nov/Dec 2003
Pg. 460-463

View Sample
Basics of Compounding: Considerations for Implementing USP Chapter <797> Pharmacy Compounding -- Sterile Preparations, Part 20: Patient or Caregiver Training, Patient Monitoring and Adverse Events Reporting, and Quality-Assurance Program
Okeke Claudia C
, Allen Loyd V Jr
Jul/Aug 2010
Pg. 328-331

Imatinib 40-mg/mL Oral Suspension
Allen Loyd V Jr
Nov/Dec 2016
Pg. 510

Using Compounded Medications for the Topical Treatment of Complex Regional Pain Syndrome Type I Following Trauma: A Case Report
Zur Eyal
Jan/Feb 2014
Pg. 14-19

Compounded Melatonin Cream for the Prevention and Treatment of Radiation Dermatitis: A Case Report
Garcia-Segura Laura Corral
, Garcia-Segura Javier Corral, Delgado Carlos Dorado, Maldonaldo Nuria Romero, Salgado Elena Cardero, Llorens Lucía Pérez
Jan/Feb 2022
Pg. 6-8

Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
Jul/Aug 2004
Pg. 269-274

Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride
Zur Eyal
Sep/Oct 2011
Pg. 358-366

Basics of Compounding: Excipients Used in Nonsterile Compounding, Part 11: Drug Tastes: Innate, Induced, and Improved
Allen Loyd V Jr
Sep/Oct 2021
Pg. 396-400

Return to Top